WO2010049390A1 - Compositions cosmétiques et dermatologiques pour la réduction des rides d'expression - Google Patents

Compositions cosmétiques et dermatologiques pour la réduction des rides d'expression Download PDF

Info

Publication number
WO2010049390A1
WO2010049390A1 PCT/EP2009/064082 EP2009064082W WO2010049390A1 WO 2010049390 A1 WO2010049390 A1 WO 2010049390A1 EP 2009064082 W EP2009064082 W EP 2009064082W WO 2010049390 A1 WO2010049390 A1 WO 2010049390A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
lys
gly
acid
skin
Prior art date
Application number
PCT/EP2009/064082
Other languages
German (de)
English (en)
Inventor
Soraya Heinen
Marianne Waldmann-Laue
Olaf HOLTKÖTTER
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2010049390A1 publication Critical patent/WO2010049390A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • compositions for reducing expression lines Cosmetic and dermatological compositions for reducing expression lines
  • the invention relates to topical cosmetic or dermatological compositions for wrinkle reduction.
  • Means and treatment methods for treating mature or intrinsically or extrinsically aged or photodamaged skin, especially for anti-wrinkle treatment, are a significant cosmetic challenge.
  • Cosmetic or dermatological topical compositions which allow improved treatment of wrinkles, particularly wrinkles, due to photoinduced skin aging are disclosed in European Patent Application EP 1 634 576 A1 and contain at least one DNA in a suitable cosmetic or dermatological carrier Repair enzyme and at least one oligopeptide which may have at least one NC 2 -C 24 acyl radical and / or be esterified.
  • a night cream exemplarily there also apple kernel extract is contained.
  • the known compositions containing at least one DNA repair enzyme and at least one oligopeptide having at least one NC 2 -C 24 acyl radical and / or esterified, also for relaxation of the muscles and thus the clearer Reduction of facial wrinkles are suitable when incorporating other ingredients in the compositions.
  • the present invention is in a first embodiment, a cosmetic or dermatological topical composition containing at least one DNA repair enzyme and at least one oligopeptide, which have at least one NC 2 -C 24 acyl radical and / or esterified, which additionally in each case based on the weight of the composition - in a cosmetically acceptable carrier: a) 0.001 to 1 wt .-% of at least one hydroxystilbene oligomer, its or their alkyl ethers and / or its or their esters, b) 0.001 to 2 wt. c) at least one oil-soluble UV filter comprising at least one alkyl- and / or alkoxy-substituted dibenzoylmethane derivative.
  • compositions according to the invention are characterized in that the DNA repair enzyme is selected from photolyase and T 4 endonuclease V and mixtures of these enzymes.
  • the DNA repair enzymes can be encapsulated both in liposomes and freely, that is to say in their encapsulated form.
  • Liposome encapsulation can preferably be carried out with phospholipids, particularly preferably with lecithin.
  • Particularly preferred according to the invention is the use of at least one liposome-encapsulated DNA repair enzyme.
  • Liposome-encapsulated photolyase is commercially available for. B. under the product name Photosomes TM (INCI name: Aqua, lecithin, plankton extract) liposome-encapsulated T4N5 z.
  • B. under the name Ultrasomes TM (INCI name: Aqua, lecithin, Micrococcus Lysate) from AGI Dermatics, USA, available.
  • the commercial products Photosomes TM or Ultrasomes TM are preferred in amounts of 0.1-10% by weight, more preferably 0.5-5.0% by weight and most preferably 1.0-0.4% by weight .-%, based on the total agent included.
  • compositions according to the invention are characterized in that at least one DNA repair enzyme is present in total amounts of 0.00001-1% by weight, preferably 0.0001-0.1% by weight, particularly preferably 0.001-0.01-0.05 Wt .-% and most preferably 0.002 - 0.005 wt .-%, is contained.
  • compositions according to the invention are characterized in that they contain 0.00001-1% by weight, preferably 0.0001-0.1% by weight, more preferably 0.001-0.05% by weight, based on the weight of the composition % and most preferably 0.002 to 0.005% by weight of at least one DNA repair enzyme from the group photolyase and T4 endonuclease V and mixtures of these enzymes.
  • oligopeptides contained in the compositions according to the invention which may also be referred to as amino acid oligomers, according to the invention are peptides having 2-30, preferably 2-15, amino acids.
  • amino acids and / or the NC 2 -C 24 -acylamino acids are selected according to the invention from alanine, arginine, asparagine, aspartic acid, canavanine, citrulline, cysteine, cystine, dipalmitoylhydroxyproline, desmosine, glutamine, glutamic acid, glycine, histidine, homophenylalanine, hydroxylysine, hydroxyproline , Isodesmosin, isoleucine, leucine, lysine, methionine, methylnorleucine, ornithine, phenylalanine, proline, pyroglutamic acid, sarcosine, serine, taurine, threonine, thyroxine, tryptophan, tyrosine, VaNn, N-acetyl-L-cysteine, zinc pyroglutamate, sodium octanoylglutamate , Sodium decanoy
  • the C 2 -C 24 acyl radical with which said amino acids on the amino group can be derivatized is selected from an acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl , Undecanoyl, lauroyl, tridecanoyl, myristoyl, pentadecanoyl, cetoyl, palmitoyl, stearoyl, elaidoyl, arachidoyl or behenoyl radicals.
  • Mixtures of C 8 -C 18 acyl radicals are also used as cocoyl radicals and are also preferred substituents.
  • the amino acids which carry an OH group can also be esterified at this OH group.
  • a preferred example of this according to the invention is hydroxyproline, which is N-acylated and esterified with two, preferably linear, C 2 -C 22 fatty acid residues, more preferably dipalmitoylhydroxyproline, which is e.g. B. Sepilift DPHP available from the company Seppic.
  • the physiologically acceptable salts of the preferred oligopeptides according to the invention are selected from the ammonium, alkali metal, magnesium, calcium, aluminum, zinc and manganese salts. Preferred are the sodium, potassium, magnesium, aluminum, zinc and manganese salts.
  • the oligomers of the amino acids and / or the NC 2 -C 24 -acylamino acids are preferably selected from di-, tri-, tetra-, penta-, hexa- or pentadecapeptides which may be N-acylated and / or esterified.
  • amino acid oligomers or oligopeptides stimulate the collagen synthesis or are able to recruit immune system cells, such as mast cells and macrophages, which then, via the release of growth factors repair processes in the tissue, eg. B. Collagen synthesis, induce, or are able to bind to the sequence Arg-Phe-Lys in thrombospondin I (TSP-1) and thus active TGF-ß (tissue growth facto ⁇ , the synthesis of collagen in dermal fibroblasts
  • TSP-1 thrombospondin I
  • TGF-ß tissue growth facto ⁇ , the synthesis of collagen in dermal fibroblasts
  • Such amino acid oligomers or oligopeptides can be used as anti-aging agents.
  • compositions according to the invention are characterized in that they contain 0.00001-1% by weight, preferably 0.0001-0.1% by weight, more preferably 0.001-0.05% by weight, based on the weight of the composition .-% and extremely preferably 0.002 to 0.005 wt .-% of at least one di-, tri-, tetra-, penta- or hexapeptide which may be acylated and / or esterified with at least one NC 2 -C 24 acyl radical, and mixtures of these substances ,
  • N-acylated and / or esterified dipeptides are acetyl-citrullyl-arginine (eg Exsy-algins of exsymol with the INCI name Acetyl Citrull Amido Arginine), Tyr-Arg (dipeptide-1), Val- Trp (dipeptide-2), Asn-Phe, Asp-Phe, N-palmitoyl-.beta.-Ala-His, N-acetyl-Tyr-Arg-hexyldecylester (eg, calmosensins from Sederma), carnosine (.beta. His) and N-palmitoyl-Pro-Arg.
  • acetyl-citrullyl-arginine eg Exsy-algins of exsymol with the INCI name Acetyl Citrull Amido Arginine
  • Tyr-Arg dipeptide-1
  • Val- Trp dipeptide-2
  • N-acylated and / or esterified tripeptides are Gly-His-Lys, z. B. under the name "Omega-CH Akt ⁇ vator" by the company GfN or in acylated form (N-palmitoyl-Gly-His-Lys) under the name Biopeptide CL is available from Sederma, but (in acylated form) also a component
  • the tri-peptide Gly-His-Lys can also be used as a copper salt (Cu 2+ ) and as such can be obtained from ProCyte Corporation, and analogs of Gly-His-Lys can be used
  • Ala, Leu and Ne are suitable for the substitution of Gly.
  • the inventively preferred amino acids which can replace His or Lys include a side chain with a nitrogen atom which is predominantly charged at pH 6, e.g.
  • N-acylated and / or esterified tetrapeptides are selected from the Rigin and Rigin-based tetrapeptides and ALAMCAT tetrapeptides.
  • Rigin has the sequence Gly-Gln-Pro-Arg.
  • Rigin-based tetrapeptides include the Rigin analogs and Rigin derivatives, in particular the invention particularly preferred N-Palm ⁇ toyl-Gly-Gln-Pro-Arg, the z. B. is available under the name Eyeliss of Sederma, but also forms part of the product Matrixyl 3000 of Sederma.
  • the Rigin analogs include those in which the four amino acids are rearranged and / or in which a maximum of two amino acids are substituted to Rigin, z.
  • the sequence AIa-Gln-Thr-Arg Preferably, at least one of the amino acids of the sequence has a Pro or Arg, and more preferably, the Tetrapeptide includes both Pro and Arg, and their order and position may vary.
  • the substituting amino acids can be selected from any amino acid defined below.
  • Especially preferred Rigin-based tetrapetides include: Xaa-Xbb-Arg-Xcc, Xaa-Xbb-Xcc-Pro, Xaa-Xbb-Pro-Arg, Xaa-Xbb-Pro-Xcc, Xaa-Xbb-Xcc-Arg, where Xaa, Xbb and Xcc may be the same or different amino acids and wherein Xaa is selected from Gly and the amino acids which may substitute Gly, Xbb is selected from GIn and the amino acids which may substitute for GIn, Xcc is selected from Pro or Arg and the amino acids, which can substitute Pro and Arg.
  • the preferred amino acids that can replace GIy include an aliphatic side chain, e.g. B. ⁇ -Ala, Ala, VaI, Leu, Pro, Sarcosine (Sar) and Isoleucine (Ne).
  • the preferred amino acids which can replace GIn include a side chain having an amino group predominantly uncharged at neutral pH (pH 6-7), e.g. Asn, Lys, Orn, 5-hydroxyproline, citrulline and canavanine.
  • the preferred amino acids which can replace Arg include a side chain having a nitrogen atom predominantly charged at pH 6, e.g. Pro, Lys, His, Desmosine and Isodesmosin.
  • ALAMCAT tetrapeptides are tetrapeptides which contain at least one amino acid with an aliphatic side chain, eg. B. ⁇ -Ala, Ala, VaI, Leu, Pro, Sarcosine (Sar) and Isoleucine (Ne). Furthermore, ALAMCAT tetrapeptides include at least one amino acid having a side chain with an amino group predominantly uncharged at neutral pH (pH 6-7), e.g. GIn, Asn, Lys, Orn, 5-hydroxyproline, citrulline and canavanine.
  • ALAMCAT tetrapeptides include at least one amino acid having a side chain with a nitrogen atom predominantly charged at pH 6, e.g. Arg, Pro, Lys, His, Desmosin and Isodesmosin.
  • ALAMCAT tetrapeptides may contain any amino acid; however, preferably the fourth amino acid is also selected from the three abovementioned groups.
  • N-acylated and / or esterified pentapeptides which are preferred according to the invention are selected from Lys-Thr-Thr-Lys-Ser and its N-acylated derivatives, particularly preferably N-palmitoyl-Lys-Thr-Thr-Lys-Ser, which can be obtained under the Matrixyl is available from Sederma, further N-palmitoyl-Tyr-Gly-Gly-Phe-Met, Val-Val-Arg-Pro-Pro, N-palmitoyl-Tyr-Gly-Gly-Phe-Leu, Gly- Pro-Phe-Pro-Leu and N-Benzyloxycarbonyl-Gly-Pro-Phe-Pro-Leu (the latter two are serine proteinase inhibitors for the inhibition of desquamation).
  • N-acylated and / or esterified hexapeptides are Val-Gly-Val-Ala-Pro-Gly and its N-acylated derivatives, particularly preferably N-palmitoyl-Val-Gly-Val-Ala-Pro-Gly available under the name Biopeptide EL from the company Sederma, furthermore Ala-Asp-Leu-Lys-Pro-Thr (hexapeptide-3, for example peptides 02 from Vincience), acetyl-hexapeptide-3 (Argireline from Lipotec), Hexapeptide-4 (e.g., Collasyn 6KS from Therapeutic Peptide Inc.
  • hexapeptyl-5 e.g., Collasyn 6VY from TPI
  • myristoyl hexapeptide-5 e.g., Collasyn 614VY from TPI
  • myristoyl Hexapeptide-6 eg Collasyn 614VG from TPI
  • Ala-Arg-His-methylnorleucine homophenylalanine-Trp hexapeptide-7
  • hexapeptide-8 eg Collasyn 6KS from TPI
  • myristoyl hexapeptide-8 eg Collasyn Lipo-6KS from TPI
  • hexapeptide-9 eg Collaxyl from Vincience
  • hexapeptide-10 eg Collaxyl from Vincience or Seriseline from Lipotec
  • Hexapeptide-11 eg, Peptamide-6 from Arch Personal Care
  • Pentadecapep- tid is z.
  • Vinci 01 by Vincience Pentadecapeptide-1
  • Another preferred amino acid oligomer is the peptide derivative L-glutamylaminoethyl-indole (glistine exsymol).
  • oligopeptides it may be particularly preferred according to the invention to use combinations of at least two oligopeptides.
  • Particularly preferred according to the invention are combinations of N-palmitoyl-Gly-His-Lys and N-palmitoyl-Gly-Gln-Pro-Arg, as obtainable, for example, in the raw material Matrixyl 3000 from Sederma.
  • compositions preferred according to the invention are characterized in that they comprise at least one oligopeptide which may contain at least one NC 2 -C 24 -acyl residue and / or be esterified and which is selected from Tyr-Arg and its N-acylated derivatives, in particular N-acylated derivatives.
  • compositions according to the invention are characterized in that at least one oligopeptide is used in total amounts of 0.000001-1% by weight, preferably 0.00001-0.1% by weight, particularly preferably 0.0001-0.001-0.01. 0.05% by weight, and most preferably 0.002-0.005% by weight
  • compositions according to the invention are characterized in that they contain 0.00001-1% by weight, preferably 0.0001-0.1% by weight, more preferably 0.001-0.05% by weight, based on the weight of the composition % and most preferably 0.002 to 0.005 wt .-% of at least one oligopeptide from the group Tyr-Arg and its N-acylated derivatives, in particular N-acetyl-Tyr-Arg-hexyl decyl ester, Gly-His-Lys and its N -acylated derivatives, in particular N-palmitoyl-Gly-His-Lys, Gly-His-Arg, and its N-acylated derivatives, in particular N-myristoyl-Gly-His-Arg, Lys-Val-Lys and its N-acylated derivatives , in particular Palmitoyl-Lys-Val-Lys, Val-Tyr VaI, Gly-Gln-Pro-Arg
  • compositions according to the invention additionally contain, based on their weight, from 0.001 to 1% by weight of at least one hydroxystilbene oligomer, its or their alkyl ethers and / or their esters or their esters.
  • Hydroxystilbenes are an extensive group of natural products, mostly phytoalexins; many of them are derived from conifers and are often present as glycosides and / or methyl ethers. But they can also be produced synthetically. Also with acids, for example with phosphoric acid, esterified hydroxystilbenes are suitable for the compositions according to the invention. Most hydroxystilbenes are in the (E) -form, but some also occur in the (Z) -form. Among the most important representatives is Pinosylvin (3,5-stilbendiol). In the (E) form, pinosylvin forms needles that are insoluble in water, soluble in acetone. (E) - u.
  • (Z) isomers occur in addition to the corresponding mono- and dimethyl ethers in pine, pine and other softwoods.
  • Piceatannol (3,3 ', 4,5-stilbentetrol, 3,3', 4,5'-tetrahydroxystilbene, astringenin) forms needles in the (E) -form. It was isolated from spruce trees.
  • oligomers of hydroxystilbenes are the dimers of resveratrol, in particular the (E) -resveratrol, the so-called viniferins, in particular the trans-epsilon-viniferin (see formula RESV-II). trans-epsilon-viniferin (RESV-II)
  • Vitisin E see formula RESV-III
  • Vitisin D see formula RESV-IV
  • trans-epsilon-viniferine is C 28 H 22 ⁇ 6 (CAS: 62218-08-0).
  • This substance in free form or as glycoside in variable amounts in various plant species, including Vitaceae, Umbelhferae, Myrtaceae, Dipterocarpaceae, Cyperaceae, Gnetaceae, legumes, Gramineae, Sericeae, Haemodoraceae, Musaceae, Polygonaceae, Pinaceae, Cupressaceae, Cesalpiniaceae, Poaceae, et Solanaceae, in particular in Balanocarpus zeylanicus, Caragana chamlagu, Caragana sinica, Carex fedia, Carex humilis, Carex kobomugi, Carex pendula, Carex pumila Thunb, Cyphostemma crotalarioides, Gnetum hainanense, Gnetum ul
  • the hydroxystilbene oligomers are particularly preferably extracted from the Vitaceae, in particular from the stems of grapes, since these are readily available in terms of quantity.
  • Suitable extractants are both water and organic solvents.
  • Preferred organic solvents are ethyl acetate and / or diethyl ether.
  • Disturbing lipids which are also extracted with, for example, can be removed by means of petroleum ether, hexane or chloroform.
  • Preferred extraction methods are carried out by means of organic solvents and microwave or ultrasound treatment, or by maceration Lixiviation or by extraction by supercritical fluids.
  • the thus enriched extracts are advantageously filtered, washed and most preferably freeze-dried.
  • oligomers of hydroxystilbenes are dimers, trimers, tetramers, pentamers and hexamers of hydroxystilbenes. Particularly preferred are the dimers, trimers and tetramers, exceptionally preferred are the dimers of hydroxystilbenes.
  • the oligomerization is carried out according to the invention particularly preferably by the attack of a hydroxyl group on the ethylenic double bond of another Hydroxystilben molecule to form a Dihydrofuranrings, as exemplified above the example of (E) - Resveratrol and the oligomers formed from trans-epsilon-viniferin, Vitisin E and Vitisin D is described.
  • oligomerization reactions are possible and may be preferred, for example the condensation of two or more hydroxystilbene molecules via the hydroxyl groups to form ether bonds. Since the oligomers formed by condensation are sterically less hindered than the oligomers formed on the ethylenic stilbene double bond, in addition to the dimers, trimers, tetramers, pentamers and hexamers also higher oligomers, such as heptamers and octamers, are possible.
  • Preferred according to the invention are the homo-oligomers, based on the non-derivatized, ie, for example, unetherified or non-esterified, hydroxystilbene monomers.
  • the derivatization of the hydroxystilbene for example the etherification or esterification of the OH groups, can take place before or after the oligomerization.
  • the derivatization after the oligomerization can lead to an unsymmetrical substitution pattern.
  • compositions according to the invention comprise, based on the weight of the composition, 0.002 to 0.75% by weight, preferably 0.003 to 0.5% by weight, more preferably 0.004 to 0.25% by weight and in particular 0.005 to 0 1% by weight of at least one hydroxystilbene oligomer from the group of the hydroxystilbene monomers of the general formula (RESV-Ia) or (RESV-Ib):
  • the alkyl group in the formulas RESV-I a and RESV-I b is preferably selected according to the invention from a methyl, ethyl, n-propyl, i-propyl, n-butyl, sec-butyl, tert-butyl - Group and 2-ethylhexyl group, more preferably selected from a methyl group.
  • the alkoxy group in the formulas RESV-I a and RESV-I b is preferably selected according to the invention from a methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, sec-butoxy, tert-butoxy Group and 2-ethylhexoxy group, more preferably selected from a methoxy group.
  • the glycoside radical in the formulas RESV-I a and RESV-I b is preferably selected according to the invention from a radical derived from D-glucose, fructose, D-galactose, L-arabinose, ribose, D-xylose, lyxose, Allose, altrose, mannose, gulose, idose, talose, fucose, and sucrose, wherein D-glucose, D-apiose, L-rhamnose, L-rhamnoglycosides, rutinose (6-0-alpha-L-rhamnopyranosyl-D-glucose) , D-glucuronic acid, D-galacturonic acid and neohesperidosis are particularly preferred.
  • the organic acid R'COOH which is used for the esterification of the compounds represented in the formulas RESV-I a and RESV-I b, is preferably selected according to the invention from the linear and branched, saturated, monounsaturated and polyunsaturated, optionally aromatic dC 30 -monocarboxylic acids, in particular formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, valeric acid, isovaleric acid, hexanoic acid, sorbic acid ((E, E) -2,4-hexadienoic acid), 2-ethylhexanoic acid, heptanoic acid, benzoic acid, octanoic acid, nonanoic acid, decanoic acid, Undecanoic acid, lauric acid, tridecanoic acid, tetradecanoic acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, o
  • Ricinoleic acid mandelic acid (hydroxyphenylacetic acid), 4-hydroxymandelic acid, malic acid (malic acid), erytharic acid, threaric acid, glucaric acid, galactaric acid, mannaric acid, gular acid, 2-hydroxy-2-methylsuccinic acid, gluconic acid, glucuronic acid, galacturonic acid and salicylic acid, wherein hexanoic acid, sorbic acid ((E, E) -2,4-hexadienoic acid), 2-ethylhexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, palmitic acid, stearic acid, glycolic acid and lactic acid are particularly preferable.
  • Particularly preferred according to the invention are the oligomers of the (E) -hydroxystilbenes, in particular the dimers of the (E) -hydroxystilbenes.
  • Hydroxystilbene oligomers particularly preferred according to the invention are formed from the following hydroxystilbene monomers:
  • Hydroxystilbene oligomers particularly preferably used according to the invention are selected from trans-epsilon-viniferin, Vitisin E and Vitisin D and mixtures thereof, furthermore selected from mono-, di-, tri-, tetra- and pentamethoxy-trans-epsilon-viniferin, trans- epsilon-viniferin mono-, di-, tri-, tetra- and pentaalkanoates, in particular trans epsilon-viniferin mono-, di-, tri-, tetra- and pentapalmitate, mono-, di-, tri-, tetra- , Penta, hexa and heptamethoxy-Vitisin E, Vitisin E-mono-, di-, tri-, tetra-, penta-, hexa- and heptaalkanoates, in particular Vitisin E-mono-, di-, tri-, tetra-
  • compositions according to the invention are characterized in that they contain, based on the weight of the composition, from 0.0015 to 0.5% by weight, preferably from 0.002 to 0.25% by weight, more preferably from 0.003 to 0.1% by weight. % and in particular 0.004 to 0.05 wt .-% trans-epsilon-viniferin, Vitisin E and Vitisin D and mixtures thereof.
  • compositions according to the invention also contain from 0.001 to 2% by weight of at least one apple seed extract.
  • An apple seed extract which is particularly preferred according to the invention is the commercial product Ederline of the manufacturer Seporga.
  • Ederline contains phytohormones, isoflavonoids, phytosterols, triterpenoids, tocopherols and natural waxes.
  • in vitro tests with cultured skin cells show effects on the synthesis of collagen type I and collagen type III as well as on fibronectin.
  • a positive effect of Ederline on the skin relief was measured in volunteer studies.
  • Ederline is once in water-soluble form as Ederline-H (INCI: PEG-40 Hydrogenated Castor OiI, PPG-2-Ceteareth-9, Pyrus Malus (Apple) Fruit Extract), and in fat-soluble form as Ederline-L (INCI., Hexyldecanol, Pyrus malus (Apple) Fruit Extract) available.
  • Suitable amounts of edderline according to the invention are from 0.1 to 10% by weight, preferably from 1 to 8% by weight and more preferably from 3 to 5% by weight, based in each case on the entire composition.
  • apple seed extracts according to the invention in amounts of 0.001 to 2 wt .-%, preferably 0.01 to 1, 6 wt .-% and particularly preferably 0.03 to 1 wt .-%, each based on the entire composition, used.
  • compositions according to the invention are characterized in that they contain, based on the weight of the composition, 0.001-2% by weight, preferably 0.01-1.6% by weight and particularly preferably 0.03-1% by weight.
  • Apple Kernel Extract (s) (based on Active Ingredient Content).
  • compositions according to the invention comprise at least one oil-soluble UV filter comprising at least one alkyl- and / or alkoxy-substituted dibenzoylmethane derivative.
  • Alkyl and / or alkoxy-substituted dibenzoylmethane derivatives which are preferred according to the invention are characterized in that one of the phenyl radicals has at least one alkyl group selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n -Pentyl, isopentyl, neopentyl, 2-ethylhexyl, and the other phenyl radical having at least one alkoxy group selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, Isopentoxy, neopentoxyl, 2-ethylhexoxy, is substituted.
  • one of the phenyl radicals has at least one alkyl group selected from methyl, ethyl,
  • Particularly preferred substituents are isopropyl, tert-butyl and methoxy.
  • Preferred alkyl- and / or alkoxy-substituted dibenzoylmethane derivatives according to the invention are selected from 2-methyldibenzoylmethane, 4-methyldibenzoylmethane, 4-isopropyldibenzoylmethane, 4-tert-butyldibenzoylmethane, 2,4-dimethyldibenzoylmethane, 2,5-dimethyldibenzoylmethane, 4,4'-diisopropyldibenzoylmethane , 4,4'-dimethoxydibenzoylmethane, 4-tert-butyl-4'-methoxydibenzoylmethane, 2-methyl-5-isopropyl-4'-methoxydibenzoylmethane, 2-methyl-5-tert-butyl-4'-me
  • 4-tert-butyl-4'-methoxydibenzoylmethane with the INCI name butyl methoxydibenzoylmethane (also referred to as 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1, 3-dione ), an oil-soluble organic sunscreen, the z. B. as PARSOL ® 1789 from DSM or as Eusolex ® 9020 from Merck KGaA is available.
  • compositions according to the invention contain, based on the weight of the composition, from 0.01 to 5% by weight, preferably from 0.05 to 4% by weight, more preferably from 0.1 to 3% by weight, particularly preferably 0, 25 to 2 wt .-% and in particular 0.5 to 1, 5 wt .-% 4- (tert-butyl) -4'-methoxydibenzoylmethane.
  • the compositions of the invention may further contain cosmetic adjuvants and other active ingredients such as are commonly used in such compositions, e.g.
  • preservatives preservatives, bactericides, perfumes, dyes, thickeners, wetting and / or moisturizing substances, fats, oils, waxes, alcohols, polyols, polymers, electrolytes, organic solvents or silicone derivatives.
  • Advantageous preservatives are, for example, formaldehyde releasers (such as, for example, DMDM hydantoin), iodopropyl butylcarbamates, parabens, phenoxyethanol, ethanol, benzoic acid and the like.
  • the preservative system preferably also comprises preserving aids, such as, for example, octoxyglycerol, 1, 2-pentanediol, 1, 5-pentanediol, 1, 2-hexanediol, 1, 6-hexanediol, 1, 2-heptanediol, 1, 2-octanediol, 1, 8-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,10-decanediol, 1,2-undecanediol, 1,2-dodecanediol, 1,2-tridecanediol or 1,2-tetradecanediol.
  • preserving aids such as, for example, octoxyglycerol, 1, 2-pentanediol, 1, 5-pentanediol, 1, 2-hexanediol, 1, 6-hexanediol,
  • compositions are also obtained when antioxidants are used as additives or active ingredients.
  • the compositions preferably contain at least one antioxidant.
  • antioxidants all suitable or customary for cosmetic and / or dermatological applications or antioxidants can be used, in particular tocopherol, tocopheryl acetate or dimethylmethoxy chromanol, available under the trade name Lipochroman-6 from Lipotec.
  • the active ingredient (s) are selected from the group comprising catechins and bile acid esters of catechins and aqueous or organic extracts of plants or plant parts which have a content of catechins or bile acid esters of catechins, such as the leaves of the plant family Theaceae, in particular Species Camellia sinensis (green tea).
  • catechins and bile acid esters of catechins and aqueous or organic extracts of plants or plant parts which have a content of catechins or bile acid esters of catechins, such as the leaves of the plant family Theaceae, in particular Species Camellia sinensis (green tea).
  • Particularly advantageous are their typical ingredients (such as, for example, polyphenols or catechins, caffeine, vitamins, sugars, minerals, amino acids, lipids).
  • Catechins represent a group of compounds which are to be regarded as hydrogenated flavones or anthocyanidins and derivatives of "catechin” (catechol, 3, 3 ', 4', 5,7-flavanpentaol, 2- (3,4-dihydroxyphenyl) -chroman -3,5,7-triol). Also epicatechin ((2R, 3R) -3,3 ', 4', 5,7-flavanpentaol) is an advantageous active ingredient in the context of the present invention
  • herbal extracts containing catechins especially extracts of green tea, such as. B. extracts from leaves of the plants of the species Camellia spec, especially the teas Camellia sinenis, C. assamica, C. taliensis or C. irrawadiensis and crosses of these with, for example, Camellia japonica.
  • Further preferred active substances are polyphenols or catechins from the group (-) - catechin, (+) - catechin, (-) - catechin gallate, (-) - gallocatechin gallate, (+) - epicatechin, (-) - epicatechin, (-) -Epi- catechin gallate, (-) - epigallocatechin, (-) - epigallocatechin gallate.
  • compositions according to the invention contain at least one flavonoid or at least one flavonoid-rich plant extract.
  • the flavonoids preferred according to the invention include the glycosides of the flavones, the flavanone, the 3-hydroxyflavone (flavonols), the aurones and the isoflavones.
  • Particularly preferred flavonoids are selected from naringin (aurantiine, naringenin-7-rhamnoglucoside), ⁇ -glucosylrutin, ⁇ -glucosylmyricetin, ⁇ -glucosylisoquercetin, ⁇ -glucosylquercetin, Dihydroquercetin (taxifolin), hesperidin (3 ', 5,7-trihydroxy-4'-methoxyflavanone-7-rhamnoglucoside, hesperitin-7-O-rhamnoglucoside), neohesperidin, rutin (3,3', 4 ', 5, 7-pentahydroxyflavone-3-rhamnoglucoside, quercetin-3-rhamnogluco
  • compositions according to the invention are characterized in that they contain at least one flavonoid in a total amount of from 0.0001 to 1% by weight, preferably from 0.0005 to 0.5% by weight and more preferably from 0.001 to 0.1% by weight. %, in each case based on the flavonoid active substance in the entire cosmetic composition.
  • compositions according to the invention comprise at least one ubiquinone or a ubiquinol or derivatives thereof.
  • Ubiquinols are the reduced form of ubiquinones.
  • the preferred ubiquinones according to the invention have the formula (UBI-I):
  • compositions according to the invention are characterized in that they contain at least one ubiquinone, ubiquinol or a derivative thereof in a total amount of 0.0001-1% by weight, preferably 0.001-0.5% by weight and particularly preferably 0.005-0, 1 wt .-%, each based on the total composition included.
  • compositions according to the invention contain silymarin.
  • Silymarin provides according to the invention earlier than uniform Substance considered active substance concentrate from the fruits of the milk thistle (Silybum marianum) dar.
  • the main constituents of the Silymarin are Silybin (Silymarin I), Silychristin (Silymarin II) and Silydianin, which belong to the group of Flavanolignane.
  • Compositions which are particularly preferred according to the invention are characterized in that they contain silymarin in amounts of 0.00001 to 1% by weight, preferably 0.0001 to 0.01% by weight and more preferably 0.005 to 0.1% by weight, in each case based on the total composition.
  • compositions according to the invention comprise at least one naturally occurring xanthine derivative selected from caffeine, theophylline, theobromine and aminophylline.
  • the naturally occurring xanthine derivatives are preferred in amounts of from 0.0001 to 1% by weight, more preferably from 0.001 to 0.5% by weight and most preferably from 0.005 to 0.1% by weight, based in each case on entire composition, included.
  • the compositions according to the invention contain ectoine.
  • Ectoin is the common name for 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylate.
  • ectoine is preferably present in amounts of from 0.0001 to 1% by weight, more preferably from 0.001 to 0.5% by weight, and most preferably from 0.005 to 0.01% by weight, based in each case on the total composition.
  • the compositions according to the invention comprise at least one natural betaine compound.
  • Naturally preferred natural betaine compounds according to the invention are naturally occurring compounds with the atomic grouping R 3 N + -CH 2 -X-COO " according to ILJPAC Rule C-816.1
  • betaine surfactants synthetic
  • ergothionein 2-mercapto-N ⁇ N ⁇ N ⁇ -trimethyl-L-histidinium Betaine of the formula (BETA-II)
  • the origin of the natural betaine compound used according to the invention may well be synthetic. Furthermore, salts and / or esters of natural betaine compounds according to the invention can preferably be used. Particularly preferred such derivatives are carnitine tartrate, propionyl carnitine and especially acetyl carnitine. Both enantiomers (D and L form) are to be used advantageously in the context of the present invention. It may also be advantageous to use any mixtures of enantiomers, for example a racemate of D and L form.
  • compositions according to the invention are characterized in that they contain at least one natural betaine compound in a total amount of 0.01 to 5 wt.%, Preferably 0.1 to 3 wt.%, Particularly preferably 0.2 to 1 wt extraordinarily preferably 0.3-0.5% by weight, based in each case on the total composition according to the invention.
  • compositions are characterized in that they contain at least one conditioning agent.
  • conditioning substances are to be understood as substances which are absorbed by keratinic materials, in particular on the skin, and improve the physical and sensory properties of both the skin and of the product as such. Conditioners smooth the top layer of the skin and make it soft and supple. Through the choice of conditioning agents (greasy - less greasy, fast or slow spreading, quickly or slowly absorbed into the skin and so on), the skin feel of the entire product can be adjusted.
  • Conditioning agents according to the invention are selected from fatty substances, in particular vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons , Di-n-alkyl ethers having a total of 12 to 36 carbon atoms, z.
  • vegetable oils such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons , Di-n-alkyl ethers having a total of 12 to 36 carbon atoms, z.
  • fatty acids especially linear and / or branched, saturated and / or unsaturated C 8 - 3 o fatty acids, fatty alcohols, particularly saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols having 4-30 carbon atoms which may be ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or propoxylated with 3-30, preferably 9-14 propylene oxide units, ester oils, ie esters of C 6 - 3 o-fatty acids with C 2 - 3 o-fatty alcohols, hydroxycarboxylic acid alkyl esters, dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol dioleate or propylene glycol di (2-ethylhexanoate), symmetrical, asymmetrical or cycl
  • Hardened triglyceride fats for example soybean lecithin, egg lecithin and cephalins, silicone compounds selected from decamethylcyclopentasiloxane, dodecamethylcyclohexasiloxane and silicone polymers which may, if desired, be cross-linked, e.g. B.
  • polydialkylsiloxanes polyalkylarylsiloxanes, ethoxylated and / or propoxylated polydialkylsiloxanes with the earlier INCI name dimethicone copolyol, as well as polydialkylsiloxanes, the amine and / or hydroxyl groups preferably substances with the INCI names dimethiconol, amodimethicone or trimethylsilylamodimethicones.
  • the amount of fatty substances used is preferably 0.1 to 99% by weight, more preferably 2 to 50% by weight and most preferably 5 to 20% by weight, based in each case on the total composition according to the invention.
  • the cosmetic or dermatological compositions according to the invention are preferably in the form of a liquid, flowable or solid oil-in-water emulsion, water-in-oil emulsion, multiple emulsion, in particular an oil-in-water-in-oil or water-in Oil-in-water emulsion, macroemulsion, miniemulsion, microemulsion, PIT emulsion, nanoemulsion, Pickering emulsion, hydrodispersion, a hydrogel, a lipogel, a mono- or multiphase solution, a foam, a powder or a mixture with at least a polymer suitable as a medical adhesive.
  • the agents may also be presented in anhydrous form, such as an oil or a balm.
  • the carrier may be a vegetable or animal oil, a mineral oil, a synthetic oil or a mixture of such oils.
  • the agents are present as microemulsions.
  • microemulsions are understood as meaning, in addition to the thermodynamically stable microemulsions, also the so-called "PIT emulsions.” These emulsions are systems containing the three components water, oil and emulsifier, which are oil-in-water at room temperature.
  • microemulsions When these systems are heated, microemulsions are formed in a certain temperature range (referred to as the phase inversion temperature or "PIT"), which convert to water-in-oil emulsions upon further heating and then O / W emulsions again
  • PIT phase inversion temperature
  • these are also present at room temperature as microemulsions or as very finely divided emulsions having an average particle diameter of less than 400 nm and in particular of about 100 to 300 nm of about 200 nm.
  • the compositions according to the invention contain at least one surface-active substance as emulsifier or dispersant.
  • Suitable emulsifiers are for example adducts of from 4 to 30 mol ethylene oxide and / or 0 to 5 mol propylene oxide onto linear fatty alcohols ⁇ Cs-C, to C 2 - C 22 fatty acids and C 8 -C 15 alkylphenols, C 2 - C 22 -fatty acid mono- and diesters of addition products of 1 to 30 mol of ethylene oxide onto C 3 -C e -polyols, in particular on glycerol, ethylene oxide and polyglycerol addition products of methylglucoside fatty acid esters, fatty acid alkanolamides and fatty acid glucamides, C 8 -C 22 - Alkylmono- and -oligoglycoside and their ethoxylated analogues, wherein Oligomermaschinesgrade of 1, 1
  • At least one nonionic emulsifier having an HLB value of 8 and below is included.
  • a particularly preferred compound R 1 -O-R 2 is behenyl alcohol.
  • emulsifiers with an HLB value of 8 and below are the adducts of 1 or 2 moles of ethylene oxide or propylene oxide with behenyl alcohol, erucyl alcohol, arachidyl alcohol or behenic acid or erucic acid.
  • the monoesters of C ie -C 3 o fatty acids with polyols such.
  • pentaerythritol trimethylolpropane, diglycerol, sorbitol, glucose or methyl glucose. Examples of such products are z.
  • compositions according to the invention are therefore characterized in that they are present in the form of a lamellar structures oil-in-water emulsion.
  • the compositions according to the invention are in the form of a water-in-oil emulsion.
  • Such water-in-oil emulsions can be formulated to have a higher viscosity so that they can be carefully sized into the skin. This supports the anti-cellulite effect of the compositions of the invention.
  • low-viscosity water-in-oil emulsions can be formulated, in particular based on the polymeric water-in-oil emulsifier PEG-30 dipolyhydroxystearate, available for. B. under the trade name Arlacel P 135 from Uniqema.
  • sprayable water-in-oil emulsions can be formulated.
  • thickeners for.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers.
  • copolymers can also be present in crosslinked form.
  • Suitable commercial products are ⁇ Sepigel 305, Simulgel ® 600, Simulgel ® NS and Simulgel ® EC company SEPPIC.
  • Further particularly preferred anionic homo- and copolymers are uncrosslinked and crosslinked polyacrylic acids
  • Such compounds are for example the commercial products Carbopol ®
  • a particularly preferred anionic copolymer contains as monomer to 80-98% unsaturated, optionally substituted C. 3 6- carboxylic acid or its anhydride and to 2 - 20%, if desired, substituted acrylic acid esters of saturated C 10 - 3 o-carboxylic acids, wherein the copolymer can be crosslinked with the aforementioned crosslinking agents.
  • Corresponding commercial products are Pemulen ® and Carbopol ® grades 954, 980, 1342 and ETD 2020 (ex BF Goodrich).
  • Suitable nonionic polymers include polyvinyl alcohols, which may be partially saponified, for. B. the commercial products Mowiol ® and vinylpyrrolidone / vinyl ester copolymers and polyvinylpyrrolidones z. B. under the trademark Luviskol ® (BASF) are sold. Further preferred additives are solvents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propylene glycol monoethyl ether, glycerol and diethylene glycol, perfume oils, substances for adjusting the pH, complexing agents such as EDTA, NTA, .beta.-alaninediacetic acid and phosphonic acids, propellants such as propane-butane. Mixtures, pentane, isopentane, isobutane, N 2 O, dimethyl ether, CO 2 and air.
  • solvents such as ethanol, isopropanol, ethylene glycol, propylene glycol, propy
  • a cosmetic or dermatological topical composition according to the invention for the non-therapeutic, cosmetic treatment and / or minimization of skin wrinkles and wrinkles, the signs of intrinsic and extrinsic skin aging, tired and / or flabby skin, UV-damaged skin and or irritated skin and the use of a cosmetic or dermatological topical composition according to the invention for non-therapeutic, cosmetic relaxation of the musculature, in particular of the facial muscles.
  • a further subject of the present invention is a non-therapeutic method for the non-therapeutic, cosmetic treatment and / or minimization of skin wrinkles and wrinkles, the signs of intrinsic and extrinsic skin aging, tired and / or flabby skin, UV-damaged skin and / or or irritated skin, which is characterized in that a cosmetic or dermatological topical composition according to the invention is applied to the skin.
  • Another object of the present invention is a non-therapeutic method for non-therapeutic, cosmetic relaxation of the muscles, in particular the facial muscles, which is characterized in that a cosmetic or dermatological topical composition according to any one of claims 1 to 8 is applied to the skin ,
  • the skin-smoothing properties of the daily fluid according to the invention were determined using the non-contact method FOITS (Fast Optical In Vivo Topometry of Human Skin).
  • the test panel included 29 subjects who twice daily applied a standardized amount of the cream of the invention to one eye for 4 weeks while the area around the other eye served as an untreated test control.
  • the skin relief was determined by means of FOITS immediately before the start of treatment and after 28 days.

Abstract

L'invention concerne des compositions aptes à réduire nettement les rides dans trois dimensions. Ces compositions contiennent au moins une enzyme de réparation de l'ADN et au moins un oligopeptide qui peut présenter au moins un reste acyle N-C2-C24 et/ou peut être estérifié. En outre, ces compositions contiennent - par rapport au poids de la composition respectivement - dans un véhicule cosmétiquement acceptable 0,001 à 1 % en poids d'un ou de plusieurs oligomères d'hydroxystilbènes, ses ou leurs éthers alkyliques et/ou ses ou leurs esters, 0,001 à 2 % en poids d'au moins un extrait de pépins de pomme, ainsi qu'au moins un filtre UV oléosoluble comprenant au moins un dérivé de dibenzoylméthane à substitution alkyle et/ou alcoxy.
PCT/EP2009/064082 2008-10-27 2009-10-26 Compositions cosmétiques et dermatologiques pour la réduction des rides d'expression WO2010049390A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008053271A DE102008053271A1 (de) 2008-10-27 2008-10-27 Kosmetische und dermatologische Zusammensetzungen zur Reduktion von Mimikfalten
DE102008053271.1 2008-10-27

Publications (1)

Publication Number Publication Date
WO2010049390A1 true WO2010049390A1 (fr) 2010-05-06

Family

ID=41683113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/064082 WO2010049390A1 (fr) 2008-10-27 2009-10-26 Compositions cosmétiques et dermatologiques pour la réduction des rides d'expression

Country Status (2)

Country Link
DE (1) DE102008053271A1 (fr)
WO (1) WO2010049390A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208473A1 (fr) * 2015-06-24 2016-12-29 日産化学工業株式会社 Matériau de base en bâtonnet comprenant un composé peptide lipidique
WO2018117156A1 (fr) * 2016-12-21 2018-06-28 日産化学工業株式会社 Base de préparation solide de type bâton pour application externe sur la peau
US10086035B2 (en) 2016-02-04 2018-10-02 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
US10493011B2 (en) 2017-08-03 2019-12-03 ALASTIN Skincare, Inc. Peptide compositions and methods for ameliorating skin laxity and body contour
US11103455B2 (en) 2018-08-02 2021-08-31 ALASTIN Skincare, Inc. Liposomal compositions and methods of use

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012205066A1 (de) * 2012-03-29 2013-10-02 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen enthaltend eine oder mehrere Substanzen die das Gen für den "Krüppel-like factor 9" (Klf9) modulieren
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE904014A (fr) * 1986-01-10 1986-05-02 Schifano Carmelo Creme pour soins du visage et de la peau.
US20030223982A1 (en) * 2000-12-20 2003-12-04 Kordula Schlotmann Use of DNA repair enzymes as MMP 1 inhibitors
FR2867977A1 (fr) * 2004-03-26 2005-09-30 Af Consulting Compositions pour limiter les rides de la peau provoquees par les contractions des muscles sous-cutanes et contenant du resveratrol et/ou de ses derives
EP1634576A1 (fr) * 2004-08-13 2006-03-15 Henkel Kommanditgesellschaft auf Aktien Préparations cosmétiques ou dermatologiques contenant des enzymes de réparation de l' ADN et des oligopeptides
DE102006046076A1 (de) * 2005-10-14 2007-04-19 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
DE102007004916A1 (de) * 2007-01-26 2008-07-31 Coty Prestige Lancaster Group Gmbh Antifalten-Kosmetikum auf Basis von Peptiden

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE904014A (fr) * 1986-01-10 1986-05-02 Schifano Carmelo Creme pour soins du visage et de la peau.
US20030223982A1 (en) * 2000-12-20 2003-12-04 Kordula Schlotmann Use of DNA repair enzymes as MMP 1 inhibitors
FR2867977A1 (fr) * 2004-03-26 2005-09-30 Af Consulting Compositions pour limiter les rides de la peau provoquees par les contractions des muscles sous-cutanes et contenant du resveratrol et/ou de ses derives
EP1634576A1 (fr) * 2004-08-13 2006-03-15 Henkel Kommanditgesellschaft auf Aktien Préparations cosmétiques ou dermatologiques contenant des enzymes de réparation de l' ADN et des oligopeptides
DE102006046076A1 (de) * 2005-10-14 2007-04-19 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen mit Oligopeptiden und Apfelextrakt
DE102007004916A1 (de) * 2007-01-26 2008-07-31 Coty Prestige Lancaster Group Gmbh Antifalten-Kosmetikum auf Basis von Peptiden

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"CAUDALIE VINOPERFECT - AUFHELLENDES SERUM", INTERNET CITATION, 21 May 2006 (2006-05-21), pages 1 - 4, XP002498574, Retrieved from the Internet <URL:http://web.archive.org/web/20060521014138/http://www.beauty-a-la-cart e.de/caudalie-vinoperfect-p-43.html> [retrieved on 20081006] *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107735107A (zh) * 2015-06-24 2018-02-23 日产化学工业株式会社 含有脂质肽型化合物的棒状基材
JPWO2016208473A1 (ja) * 2015-06-24 2018-04-12 日産化学工業株式会社 脂質ペプチド型化合物を含有するスティック状基材
WO2016208473A1 (fr) * 2015-06-24 2016-12-29 日産化学工業株式会社 Matériau de base en bâtonnet comprenant un composé peptide lipidique
US10688147B2 (en) 2016-02-04 2020-06-23 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
US10086035B2 (en) 2016-02-04 2018-10-02 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
US10286030B2 (en) 2016-02-04 2019-05-14 Alastin Skincare, Inc Compositions and methods for invasive and non-invasive procedural skincare
US11426443B2 (en) 2016-02-04 2022-08-30 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
US11426442B2 (en) 2016-02-04 2022-08-30 ALASTIN Skincare, Inc. Compositions and methods for invasive and non-invasive procedural skincare
WO2018117156A1 (fr) * 2016-12-21 2018-06-28 日産化学工業株式会社 Base de préparation solide de type bâton pour application externe sur la peau
JPWO2018117156A1 (ja) * 2016-12-21 2019-10-31 日産化学株式会社 スティック状皮膚外用固形基材
CN110087630A (zh) * 2016-12-21 2019-08-02 日产化学株式会社 棒状皮肤外用固体基材
US10493011B2 (en) 2017-08-03 2019-12-03 ALASTIN Skincare, Inc. Peptide compositions and methods for ameliorating skin laxity and body contour
US11052032B2 (en) 2017-08-03 2021-07-06 ALASTIN Skincare, Inc. Peptide compositions and methods for ameliorating skin laxity and body contour
US11752084B2 (en) 2017-08-03 2023-09-12 ALASTIN Skincare, Inc. Methods for fat reduction or elimination of lipid droplets
US11103455B2 (en) 2018-08-02 2021-08-31 ALASTIN Skincare, Inc. Liposomal compositions and methods of use

Also Published As

Publication number Publication date
DE102008053271A1 (de) 2010-04-29

Similar Documents

Publication Publication Date Title
EP1790330A2 (fr) Compositions cosmétiques et dermatologiques comprenant des oligopeptides et un extrait de pommes
JP7209672B2 (ja) 化粧品及び化粧品を製造するための方法
EP1634576A1 (fr) Préparations cosmétiques ou dermatologiques contenant des enzymes de réparation de l&#39; ADN et des oligopeptides
WO2010049389A1 (fr) Compositions cosmétiques et dermatologiques pour la réduction tridimensionnelle des rides
EP1803435B1 (fr) Compositions cosmétiques dotées d&#39;une protection contre les rayonnements solaires sur la base d&#39;émulsions lamellaires
WO2013092080A1 (fr) Produit pour le soin du corps avec hydratation dermique améliorée
WO2010049390A1 (fr) Compositions cosmétiques et dermatologiques pour la réduction des rides d&#39;expression
DE102005063062A1 (de) Synergistische Proteinhydrolysat-Kombinationen zur Behandlung reifer Haut
EP1640041A2 (fr) composition cosmétique ou dermatologique pour le traitement du vieillissement de la peau ou pour le traitement de la peau endommagée par la lumière
EP1776087A1 (fr) Compositions cosmetiques et dermatologiques a base de (2-hydroxyethyl)uree
DE102006060439A1 (de) Verbesserung der Hautverträglichkeit von hyperämisierenden Wirkstoffen
EP2005941A2 (fr) Compositions rajeunissant les cellules
DE102009045981A1 (de) Antifalten-Kosmetikum mit Strandkamillenextrakt
EP2266529A2 (fr) Cosmétique de protection UV
WO2013091975A1 (fr) Compositions biomimétiques pour le nettoyage et les soins de la peau
EP2253305A2 (fr) Traitement de la peau pour affiner les pores
KR20180027375A (ko) 식물 태지 성분을 포함하는 피부 보습용 화장료 조성물
DE102008054118A1 (de) Wirkstoffkombination zur Behandlung reifer Haut I
EP2263643A2 (fr) Cosmétique antiride comprenant des extrait de plants
DE102009017612A1 (de) Hautbehandlungsmittel gegen Hautalterung I
DE102009037537A1 (de) Antifalten-Kosmetikum
EP1776084A1 (fr) Compositions cosmetiques pour traiter une peau stressee contenant de la taurine et des alcools gras a chaine longue
DE102006062501A1 (de) Kosmetische und dermatologische Öl-in-Wasser-Emulsionen mit selbstkonservierenden Eigenschaften
DE102006062566A1 (de) Kosmetische und dermatologische Zusammensetzungen gegen unreine Haut und/oder Akne
DE102010026465A1 (de) Kosmetikum zur Verbesserung der Struktur gealterter Haut

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09740154

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09740154

Country of ref document: EP

Kind code of ref document: A1